Search

everythinglearnresearchcommunity

for

Search:↓

The user is experiencing promising hair regrowth after 10 weeks of using oral minoxidil and finasteride, with noticeable new hair growth. They report no significant side effects, except for some unexpected hair growth in new areas.

Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.

The user is experiencing less hair shedding and new hair growth after 57 days on finasteride 1mg and using a derma stamp. They are advised to use ketoconazole shampoo for scalp greasiness and consider adding minoxidil for better results.

The user experienced hair regrowth after starting a treatment regimen on New Year's, which includes oral finasteride, a mix of topical minoxidil with other solutions to reduce irritation, multivitamins, omega-3, vitamin D, anti-dandruff shampoo, and rosemary oil. The user noted significant progress despite initial shedding.

Researchers at the University of Virginia discovered a new group of stem cells in hair follicles that could potentially restore hair growth. The findings suggest that activating these stem cells might offer a new way to combat hair loss, though practical treatments are still years away.

ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.

Switching from tretinoin to tazarotene with minoxidil led to new hair regrowth after years of maintenance. Tazarotene's selectivity and higher concentration might be more effective for hair growth.

The user experienced increased hair shedding after switching to a new treatment with higher doses of finasteride (0.3%), minoxidil (7%), ketoconazole (2.2%), and biotin (0.2%). They are curious about the shedding but not concerned about noticeable thinning.

The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.

Switching from finasteride to dutasteride for hair loss can cause increased shedding, which may indicate the treatment is working by replacing old hairs with new ones. The original poster is experiencing aggressive hair thinning despite long-term treatment.

A user reports significant hair density increase and new growth at the temples after two months of using finasteride, minoxidil, ketoconazole, dermarolling, MK-677, zinc, and vitamin D3, with shedding stopping a week ago. They recently added MK-677 to their regimen.

The conversation is about whether doctors are offering hair transplants using verteporfin. Dr. Bargouthi in Jordan and Dr. Bloxham in New York are currently conducting trials on it.

The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.

The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.

The conversation discusses the potential availability of a new hair loss treatment, GT20029, on the grey market, with users suggesting it could be within a year but advising against using grey market products due to safety concerns and complexity of the drug.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.

The conversation discusses skepticism about the effectiveness of new hair loss treatments, mentioning that despite 40 years of research, only accidental discoveries like Minoxidil and Finasteride have been made. It also notes that drug development is a slow process, often taking a decade or more to bring a new drug to market.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

Han Bio plans to start clinical trials for a new hair multiplication technology this year, which could significantly reduce the cost and time of hair transplantation. The technology uses a single hair strand to cultivate enough cells for 30,000 hair strands.

A 21-year-old experiencing hair loss noticed reduced hair fall and new growth after using rosemary oil and amla, but results are slow. Users suggest natural remedies may not be effective long-term and recommend consulting a dermatologist or considering finasteride for better results.

The user is using dutasteride and minoxidil for hair loss and noticed new hair growth after initially thinking there was no progress. Encouragement was given to continue the treatment as it takes time to see full results.

The conversation discusses hair loss treatment progress using dutasteride and oral minoxidil over five months. The user is concerned about shedding and hopes the new hairs are healthy.

PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.

The user has been using finasteride for two years without results and recently started a new routine involving derma stamping, retinol, and minoxidil, which seems to show progress. The user microneedles about half the week and uses L’Oréal night serum for retinol.

The user started using finasteride and minoxidil three months ago and reports new hair growth with no side effects. The regimen includes minoxidil foam 5% twice daily, finasteride 1.25 mg daily, and weekly microneedling.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

The user has been using minoxidil and finasteride for 8 months and is questioning if new baby hairs are growing. Opinions vary, with some suggesting the hairs are signs of regrowth and others suggesting delusion.